Clinical trial · no report yet · Phase 2
PARERE
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
- NCT04787341 ↗
- Completed
- Gruppo Oncologico del Nord-Ovest
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 19 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Study of Panitumumab Rechallenge Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-type Chemorefractory Mestastatic Colorectal Cancer Patients
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Colorectal Cancer
- Interventions
- Regorafenib; Panitumumab
- Arms
- Panitumumab followed by Regorafenib · Active comparator
- Regorafenib followed by Panitumumab · Experimental
- Enrollment
- 213
- Primary outcomes
- Overall survival
- Sponsor
- Gruppo Oncologico del Nord-Ovest with Bayer, Amgen
- Start
- Dec 15, 2020
- Primary completion
- Aug 7, 2025
- Results posted
- No
- Registry record
- NCT04787341 · updated Aug 28, 2026
Publications
linked from the registry- Ciraci P, Germani MM, Pietrantonio F, Manca P, Lonardi S, Busico A, Bergamo F, Burgio V, Mannavola F, Di Donato S, Fenocchio E, Palermo F, Capone I, De Grandis MC, Pella N, Scartozzi M, Antonuzzo L, Passardi A, Claravezza M, Salvatore L, Tamberi S, Randon G, Conca E, Conca V, Antoniotti C, Moretto R, Masi G, Boni L, Rossini D, Cremolini C; GONO Foundation Investigators. Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. Ann Oncol. 2026 Jan;37(1):79-91. doi: 10.1016/j.annonc.2025.10.002. Epub 2025 Oct 18. PubMed 41115464